[SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]

Grati H, Jebali MC, Harzallah N, Jameleddine M
Record ID 32018011328
Original Title: SKYRIZI® (Risankizumab) dans le traitement du psoriasis en plaques modéré à sévère chez l’adulte
Authors' results and conclusions: Clinical and economic implications of SKIRIZI (risankizumab) in the treatment of moderate to severe plaque psoriasis in adult
Authors' methods: Rapid review of literature
Project Status: Completed
Year Published: 2022
Requestor: Regulatory authorities
English language abstract: There is no English language summary available
Publication Type: Rapid Review
Country: Tunisia
MeSH Terms
  • Psoriasis
  • Adult
  • Antibodies, Monoclonal
  • Psoriasis
  • Risankizumab (SKYRIZI®)
  • plaque psoriasis
  • Efficacy
  • cost effectiveness
Organisation Name: National Authority for Assessment and Accreditation in Healthcare (INEAS)
Contact Address: 30 Rue Ibn Charaf, Tunis 1002, Tunisia
Contact Name: Mouna Jameleddine
Contact Email: monajameleddine@gmail.com
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.